iM Securities downgraded Samsung Biologics' target price from 2.2 million won to 1.9 million won on July 24 while maintaining its Buy rating, adjusting facility investment estimates following Plant 6 construction and Campus 3 updates. Analyst Jeong Jae-won cited Q2 earnings results and the Polypeptide Group acquisition as factors in the valuation revision. Samsung Biologics reported Q2 operating profit of 586.4 billion won, a 23% year-over-year increase but slightly below the 599.7 billion won consensus, as costs from the US Rockville facility and Plant 5 were recognized before revenue generation. The company announced a 2.7 trillion won acquisition of Swiss peptide CDMO firm Polypeptide Group on July 20, aligning with industry trends toward geographic diversification. iM Securities noted that Plants 1-4 maintained full capacity operation during Q2, with revenue from Plant 5 and the US facility expected to begin in Q3.
iM Securities Adjusts Samsung Biologics Target Price to 1.9M Won
iM Securities analyst Jeong Jae-won stated in a July 24 report that the firm adjusted facility-related investment figures after reflecting Q2 earnings and updates on Plant 6 construction and Campus 3 development. The target price reduction from 2.2 million won to 1.9 million won incorporates revised capital expenditure estimates for these expansion projects. The firm maintained its Buy rating on Samsung Biologics shares.
Samsung Biologics Reports Q2 Operating Profit of 586.4B Won
Samsung Biologics' Q2 operating profit reached 586.4 billion won, representing 23% year-over-year growth but falling slightly short of the 599.7 billion won consensus estimate. Jeong attributed the variance to pre-revenue cost recognition from the US Rockville production facility and Plant 5. Plants 1 through 4 operated at full capacity during Q2, according to the analyst's report.
Plant 5 and US Facility Revenue Expected in Q3
Revenue generation from Plant 5 and the US facility is expected to commence in Q3. Samsung Biologics plans to establish a sales office in the Netherlands during Q3, completing its operational presence across the three core global markets of the US, Asia, and Europe. Jeong stated that this geographic footprint enables rapid response to regional customer demand and facilitates communication with local clients, which can lead to new contract wins.
Samsung Biologics Acquires Polypeptide Group for 2.7T Won
Samsung Biologics announced on July 20 its acquisition of Polypeptide Group, a Switzerland-based peptide CDMO company, for 2.7 trillion won through an all-cash tender offer for 100% of issued shares. The company's largest shareholder, Draupnir Holding B.V., holds a 55.65% stake and has committed to participate in the tender offer. Jeong assessed that transaction uncertainty has been resolved, as securing approximately 10% of the free float would achieve the target ownership level.
All regulatory approvals and closing procedures are scheduled for completion by the end of this year. Upon completion, Polypeptide Group will be delisted from the Swiss Exchange (SIX) and become a wholly owned subsidiary of Samsung Biologics.
Polypeptide Group was established in 1996 as a spinoff from Ferring Pharmaceuticals' peptide production division. The company possesses approximately 70 years of peptide active pharmaceutical ingredient (API) manufacturing experience and has secured over 1,000 track records globally. Polypeptide currently participates as a key manufacturing partner in more than 30% of global Phase 3 peptide clinical trials.
The company operates production sites in five countries including its Switzerland headquarters, spanning the US, Europe, and Asia. Jeong noted that this geographic distribution aligns with the growing industry trend toward site diversification.
FAQ
Why did iM Securities lower Samsung Biologics' target price on July 24?
iM Securities reduced the target price from 2.2 million won to 1.9 million won after adjusting facility investment estimates related to Plant 6 construction and Campus 3 development, incorporating Q2 earnings results and updates disclosed during the earnings announcement.
What did Samsung Biologics announce on July 20 regarding Polypeptide Group?
Samsung Biologics announced a 2.7 trillion won all-cash tender offer to acquire 100% of Polypeptide Group, a Switzerland-based peptide CDMO company. The transaction is expected to close by year-end following regulatory approvals, after which Polypeptide will become a wholly owned subsidiary and delist from the Swiss Exchange.
